rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    INVA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Innoviva gains new Overweight at Piper Sandler on diversified strategy
      9h agoSeeking AlphaINVAPIPR
      Piper Sandler initiates Innoviva stock with overweight rating
      18h agoInvesting.comINVA
      Innoviva earnings missed by $1.56, revenue fell short of estimates
      Nov 5Investing.comINVA
      Innoviva (INVA) Tops Q3 Earnings Estimates
      Nov 4Yahoo FinanceINVA
      Innoviva: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceINVA
      Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress

      BURLINGAME, Calif., November 04, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2026, and highlighted select corporate progress and achievements.

      Nov 4Yahoo FinanceINVA
      Innoviva And Its Real Value (NASDAQ:INVA)
      Oct 27Seeking AlphaINVA
      Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
      Oct 19Yahoo FinanceINVA
      Do Options Traders Know Something About Innoviva Stock We Don't?
      Oct 12Yahoo FinanceINVA
      Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?
      Oct 8Yahoo FinanceINVA
      Should Value Investors Buy Innoviva (INVA) Stock?

      Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

      Oct 8Yahoo FinanceINVA
      Innoviva at H.C. Wainwright conference: growth shifts to specialty drugs
      Sep 14Investing.comINVA
      Innoviva at Cantor conference: growth bets beyond COPD royalties
      Sep 10Investing.comINVA
      Innoviva to Participate in Upcoming Investor Conferences

      BURLINGAME, Calif., September 02, 2026--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:

      Sep 2Yahoo FinanceINVA
      Cantor Fitzgerald reiterates Innoviva stock rating at overweight
      Aug 21Investing.comINVA

      This is the newest page. Registered accounts read further back.